Project Grant HT94252310470
Award Date
6/15/23
Completion Date
12/14/25
Dollars Obligated
$3.9M
Federal Agency
Defense Health Agency
Awardee
DTX Pharma Inc. (QH4NQ868H5V7)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
San Diego, CA 92121, USA
Similar Awards
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $660,000.00 in funding to Nucyrna Therapeutics Inc. in Framingham, MA to develop a SOD1-targeting iRNASO oligonucleotide drug candidate with improved efficacy and safety compared to tofersen. The award has a performance period from July 1, 2025 to June 30, 2027. The Military Medical Research and Development program supports advanced biomedical research...
The federal Project Grant award ID HT94252510342, totaling $405,341.00, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program. The award supports the use of proresolution and restorative pharmacology approaches for Duchenne muscular dystrophy (DMD) therapy at the Children's Research Institute, a non-profit pediatric research organization in Washington, D.C. The award will fund advanced biomedical research and development focused...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $544,892 to the University of Texas Health Science Center at Houston to develop a novel peptide-drug conjugate for precision-targeted DNA damage in neuroendocrine tumors. The award commenced on August 1, 2025 and is set to conclude on July 31, 2028. The goal of this research is to transform healthcare for military service members, veterans, and the broader...
This federal Project Grant award, valued at $319,151.00, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports research conducted by The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF) on a novel miR-155 therapy for the treatment of peripheral neuropathy. The project aims to develop new treatments, diagnostic tools, and clinical practice guidelines to improve the health and...
This federal Project Grant award, totaling $431,750.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant will support research conducted by the University of Houston System to investigate the role of H19X noncoding RNAs in the pathogenesis of myotonic dystrophy type I. The award duration is from December 1, 2024 to November 30, 2026. The Military Medical Research and Development program funds advanced biomedical...
The federal Project Grant award of $109,632 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program to Radar Therapeutics Inc. in Berkeley, CA. The award, effective August 1, 2025 through July 31, 2026, will support research on the "Selective Translation of LNP-Delivered mRNA for Precision Therapeutics in Rare Cancers including Peripheral T-Cell Lymphoma." This advanced biomedical research aims to transform healthcare for...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $676,117 to The Children's Hospital of Philadelphia Research Institute to conduct research on expanded GAA-GGA chimeric repeats in Friedreich ataxia. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical research to address critical health challenges. The award period runs...
The U.S. Defense Health Agency awarded a $777,659 Project Grant to the Children's Research Institute in Washington, D.C. under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research to transform healthcare for military service members, veterans, and the public, with a focus on innovative research addressing critical health challenges. Specifically, the award will fund the "Use of ProResolution and Restorative Pharmacology...
This $854,060 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) was provided to Formation Venture Engineering Foundry Inc., a for-profit biotech firm, to develop an FC-fusion protein active vaccine for the prevention and treatment of C9ORF72 ALS/FTD, a rare neurodegenerative disease. The award period is from Apr 15, 2024 to Apr 14, 2026. The Military Medical Research and Development program supports innovative biomedical research...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,003,539.00 to The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. to conduct AI-based screening of ultralarge chemical libraries to identify selective muscarinic receptor antagonists as potential peripheral neuropathy therapeutics. The award period runs from April 1, 2025 through March 31, 2028. The Military Medical...